HomeNDC LookupDrug shortages › Conivaptan Hydrochloride Injection

Conivaptan Hydrochloride Injection shortage

Conivaptan Hydrochloride Injection is currently listed in shortage by the FDA. The FDA lists 1 affected product. The reported reason: Delay in shipping of the drug. This page was last refreshed from FDA data on Sep 21, 2026.

Current ⚠ Supply risk: High Cardiovascular 1 product 1,652 days · 4.5 yr First posted Mar 14, 2022 Updated Sep 16, 2026
Here’s the bottom line

Conivaptan hydrochloride injection (20 mg/100 mL) is currently unavailable due to a shipping delay reported by Cumberland Pharmaceuticals, with no estimated recovery date. No other manufacturers of this medicine are on record, so there is no available source right now.

Don’t stop or change your therapy on your own — ask your pharmacist about other manufacturers and your prescriber about a long-term plan.

Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →
1
Affected NDCs
1
Reporting manufacturers
0/1
Reporting mfrs supplying
0/1
Affected strengths supplied
100%
NDCs unavailable
1,652
Days in shortage
Source: FDA Drug Shortages Database API (openFDA). Last refreshed Sep 21, 2026 · today

What’s in shortage — at a glance

These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Conivaptan Hydrochloride Injection. Other makers that haven’t reported a problem are shown in the green card below.

Availability of affected NDCs
From the FDA shortage report
1 NDCs
Unavailable 1
Affected strengths still supplied
Among manufacturers reporting this shortage
0/1 strengths
No supply 1
FDA-reporting manufacturers with supply
Among manufacturers reporting this shortage
0/1 makers
No supply 1
Other manufacturers
We couldn’t automatically confirm other manufacturers of Conivaptan Hydrochloride Injection that aren’t reporting a shortage. Ask your pharmacist whether a different manufacturer or strength can be ordered.
Shortage timeline
  1. Sep 16, 2026
    Currently in shortage
    1 of 1 product affected.
  2. Mar 14, 2022
    First reported to the FDA
    1 product first listed.

Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.

What exactly is on backorder — by manufacturer

Manufacturer: Cumberland Pharmaceuticals Inc. 📞 800-706-5575 1 NDC click to expand
Status NDC / product Strength Availability Related information Reason
Current Vaprisol Dextrose In Plastic Container, Injection, 20 mg/100 mL (NDC 66220-160-10) NDC 66220-0160-10 Unavailable Estimated recovery: TBD Delay in shipping of the drug

These rows are manufacturer reports to the FDA for Conivaptan Hydrochloride Injection — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Conivaptan Hydrochloride Injection? options further down this page.

Why is Conivaptan Hydrochloride Injection in shortage?

Right now, Cumberland Pharmaceuticals is having trouble getting their version of conivaptan hydrochloride (Vaprisol) shipped out. Specifically, the 20 mg/100 mL bag in the plastic container (the 10-pack) is currently unavailable because of a shipping delay — meaning the product may be ready, but it's not making it through the distribution process on time. Unfortunately, Cumberland hasn't given a firm date for when this will be resolved, so the recovery timeline is listed as "to be determined."

Because this is a shipping issue rather than a manufacturing stoppage, the situation could change, but there's no estimated return date to share just yet.

FDA reason code(s): Delay in shipping of the drug

Based on the manufacturer-reported reason(s) and notes on file with the FDA for Conivaptan Hydrochloride Injection, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.

What should I do if I take Conivaptan Hydrochloride Injection?

Conivaptan Hydrochloride Injection is currently on the FDA drug-shortage list. I want to walk you through what this means so you know what to expect and what steps make sense.

The one strength on this record, 20 mg/100 mL, has no available source reported right now. This is the only strength listed, and there are no other strengths showing supply at this time. The reported reason is a delay in shipping of the drug, and only one manufacturer is on this record. An estimated recovery date has not yet been set (listed as TBD), and this shortage has lasted more than a year.

Even so, this report reflects only the manufacturer that filed it, so it does not mean every supplier is out. Here is what you can do:

  • Do not stop, skip, or change your dose on your own.
  • Ask your pharmacy to check wholesalers and other manufacturers, since this is a hospital-administered injection and local availability can differ from national data.
  • If your dose cannot be found, ask your prescriber or pharmacist about options they can choose for you.
  • Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle these calls.

This is general, manufacturer-reported information and may not match your local stock, so please lean on your care team for guidance.

If you are a patient:
  • Don’t stop or change the medication on your own — talk to your prescriber first.
  • If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
  • Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
  • Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.

Other drugs in the same treatment class

These are different medicines — not other versions of Conivaptan Hydrochloride Injection — that fall in the same broad treatment class (arginine vasopressin (avp) receptor antagonists) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.

Identity & classification

GCN Seq No 064960
GCN 19477
HICL code 036183
Ingredient (HICL) Conivaptan Hcl In 5 % Dextrose
HIC1 code R
Therapeutic class — broad (HIC1) Kidney/Urinary Tract
HIC2 code R1
Therapeutic class — intermediate (HIC2) Affect Primarily Kidneys/Urinary Tract
HIC3 code R1N
Therapeutic class — specific (HIC3) Arginine Vasopressin (Avp) Receptor Antagonists
AHFS code 40:28.28.00
AHFS class Vasopressin Antagonists
FDB label name VAPRISOL-DEXTROSE 20 MG/100 ML
FDB brand name Vaprisol-5% Dextrose
Legend status F — Federal legend — prescription drug or device
Where does this data come from?
Identity codes come from First Databank (FDB) (HICL ingredient, HIC1–3 therapeutic-class hierarchy, GCN, AHFS class, legend status) and Medi-Span GPI, mapped from a representative affected NDC. Licensed reference data — for identification only.

Other cardiovascular shortages

Conivaptan Hydrochloride Injection shortage FAQs

Is Conivaptan Hydrochloride Injection in shortage?
Yes — the FDA currently lists Conivaptan Hydrochloride Injection in shortage (status: “Current”, first reported Mar 14, 2022). 1 of 1 product is affected. This is national, manufacturer-reported data, so your pharmacy may still have stock.
Why is Conivaptan Hydrochloride Injection in shortage?
The manufacturer-reported reason on file with the FDA: Delay in shipping of the drug.
Which products are affected?
Vaprisol Dextrose In Plastic Container, Injection, 20 mg/100 mL (NDC 66220-160-10) (NDC 66220-0160-10). The full per-NDC list (availability, manufacturer and status) is in the table above — each NDC links to its own page.
When will Conivaptan Hydrochloride Injection be available again?
The FDA does not publish a guaranteed restock date, and no estimated-recovery note is on file. Availability can change daily — confirm with your pharmacy.
What should I do if I take Conivaptan Hydrochloride Injection?
Don’t stop or change it on your own. Ask your pharmacist whether they can order it from another manufacturer or a different strength/package size, and ask your prescriber about a long-term plan before your supply runs out.

Still have a question about the Conivaptan Hydrochloride Injection shortage?

Ask a pharmacist about this shortage →
How to read the Supply-Risk rating
Low (1–2)Multiple manufacturers still supplying and most strengths or pack sizes sourceable.
Medium (3)Some constraint — fewer suppliers or a notable share of NDCs unavailable.
High (4–5)Down to a single source, most strengths or pack sizes unsourceable, or a long-running outage.
Where does this data come from?
Shortage records come from the FDA Drug Shortages Database API via openFDA (/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.
Data structure & sourcing designed and verified by Dr. Brian Staiger, PharmD.
← Back to all current drug shortages